Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597807 | 0.95 | PPARA (0.52) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL14003009 | 0.95 | PPARA (0.52) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL7365429 | 0.91 | CTSL (0.53) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL22404737 | 0.91 | CTSS (0.64) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL3355326 | 0.91 | CTSS (0.64) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL85543 | 0.91 | CTSS (0.64) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL23729805 | 0.90 | CTSS (0.54) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL3439020 | 0.89 | CTSS (0.53) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL7409389 | 0.89 | CTSS (0.65) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL1486267 | 0.89 | CTSS (0.63) | PPARACTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4496837-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | The Research Foundation for The State University of New York (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023178107-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178107-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4097092-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Protego Biopharma, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115298168-A | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | 普罗泰格生物制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021154842-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | PPARA 2559/4885CTSS 468/4885CTSK 1005/4885 |
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | PPARA 3903/4885CTSS 1089/4885CTSK 2241/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | PPARA 4008/4885CTSS 1089/4885CTSK 2292/4885 |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | PTMS, PSMG3, PSMB3 | PPARA 3011/4885CTSS 3065/4885CTSK 3616/4885 |
| US-20040224955-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | PPARA 3903/4885CTSS 1089/4885CTSK 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.